214 related articles for article (PubMed ID: 27412013)
1. Over-expression of DNA-PKcs in renal cell carcinoma regulates mTORC2 activation, HIF-2α expression and cell proliferation.
Zheng B; Mao JH; Li XQ; Qian L; Zhu H; Gu DH; Pan XD
Sci Rep; 2016 Jul; 6():29415. PubMed ID: 27412013
[TBL] [Abstract][Full Text] [Related]
2. DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-SIN1 association mediates ultraviolet B (UVB)-induced Akt Ser-473 phosphorylation and skin cell survival.
Tu Y; Ji C; Yang B; Yang Z; Gu H; Lu CC; Wang R; Su ZL; Chen B; Sun WL; Xia JP; Bi ZG; He L
Mol Cancer; 2013 Dec; 12(1):172. PubMed ID: 24365180
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.
Zheng B; Mao JH; Qian L; Zhu H; Gu DH; Pan XD; Yi F; Ji DM
Cancer Lett; 2015 Feb; 357(2):468-75. PubMed ID: 25444920
[TBL] [Abstract][Full Text] [Related]
4. Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo.
Pan XD; Gu DH; Mao JH; Zhu H; Chen X; Zheng B; Shan Y
PLoS One; 2017; 12(3):e0172555. PubMed ID: 28257457
[TBL] [Abstract][Full Text] [Related]
5. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
7. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR; Sun SY
J Biol Chem; 2013 May; 288(19):13215-24. PubMed ID: 23536185
[TBL] [Abstract][Full Text] [Related]
8. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma.
Li W; Chen C; Zhao X; Ye H; Zhao Y; Fu Z; Pan W; Zheng S; Wei L; Nong T; Li Z; Chen R
J Cell Mol Med; 2017 Nov; 21(11):2896-2908. PubMed ID: 28544376
[TBL] [Abstract][Full Text] [Related]
9. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
10. Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation.
Nayak BK; Feliers D; Sudarshan S; Friedrichs WE; Day RT; New DD; Fitzgerald JP; Eid A; Denapoli T; Parekh DJ; Gorin Y; Block K
Oncogene; 2013 Jun; 32(26):3147-55. PubMed ID: 22869144
[TBL] [Abstract][Full Text] [Related]
11. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
12. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
Hao P; Kang B; Li Y; Hao W; Ma F
Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
[TBL] [Abstract][Full Text] [Related]
13. DNA-PKcs-SIN1 complexation mediates low-dose X-ray irradiation (LDI)-induced Akt activation and osteoblast differentiation.
Xu Y; Fang SJ; Zhu LJ; Zhu LQ; Zhou XZ
Biochem Biophys Res Commun; 2014 Oct; 453(3):362-7. PubMed ID: 25264192
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2α expression in human renal cell carcinoma.
Maru S; Ishigaki Y; Shinohara N; Takata T; Tomosugi N; Nonomura K
J Urol; 2013 May; 189(5):1921-9. PubMed ID: 23147251
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
Harada K; Miyake H; Kumano M; Fujisawa M
Br J Cancer; 2013 Oct; 109(9):2389-95. PubMed ID: 24091619
[TBL] [Abstract][Full Text] [Related]
16. KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms.
Chen MB; Zhou ZT; Yang L; Wei MX; Tang M; Ruan TY; Xu JY; Zhou XZ; Chen G; Lu PH
Oncotarget; 2016 Mar; 7(13):17047-59. PubMed ID: 26933997
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth.
Zheng B; Sun X; Chen XF; Chen Z; Zhu WL; Zhu H; Gu DH
Aging (Albany NY); 2020 Oct; 12(20):20445-20456. PubMed ID: 33109772
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo.
Xing ZY; Wang Y; Cheng L; Chen J; He XZ; Xing W
Cell Physiol Biochem; 2018; 50(2):640-653. PubMed ID: 30308518
[TBL] [Abstract][Full Text] [Related]
19. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.
Wu L; Zhang J; Wu H; Han E
Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179
[TBL] [Abstract][Full Text] [Related]
20. MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis
Yan F; Wang Q; Xia M; Ru Y; Hu W; Yan G; Xiong X; Zhang M; Wang J; Li Q; Zhang B; Wang H; Lin W; Wu G; Li X
Cancer Biol Med; 2021 Dec; 19(6):818-35. PubMed ID: 34931765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]